GLP-1 Receptor Agonists Linked to Small Hypersomnolence Risk Increase
TL;DR: A 2026 real-world cohort study in Journal of Diabetes & Metabolic Disorders linked GLP-1 receptor agonists, drugs targeting a glucose-related metabolic hormone pathway, to a higher hazard of new hypersomnolence, but the absolute risk increase was small.…
Read article